Given this evidence, the present trial aimed to assess whether marine ω-3 PUFA supplementation enhances FFAR4 activation in PBMCs and thereby contributes to the reduction in inflammatory markers in individuals with obesity. The gene discussed is FFAR4; the disease is obesity disorder.